NCT00725855

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

A Single-Center, Double-Blind, Placebo-Controlled, Randomized Blocks Study Investigating the Effect of 4 Dosages (1 mg, 5 mg, 15 mg, 50 mg) of MEM 3454 on P50 Sensory Gating and Mismatch Negativity (MMN) in Patients With Schizophrenia

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Memory Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50 sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize the P50 ratio. Data produced in this study will provide useful information regarding the value of P50 as an efficacy biomarker, and provide evidence for the optimal dosing of MEM 3454 for additional P50 studies.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	MEM 3454	1 mg dose
DRUG	MEM 3454	5 mg dose
DRUG	MEM 3454	15 mg dose
DRUG	MEM 3454	50 mg dose
DRUG	Placebo for MEM 3454	Placebo dose

Timeline

• Start date: 2008-08-01
• Primary completion: 2009-03-01
• Completion: 2009-04-01
• First posted: 2008-07-31
• Last updated: 2008-07-31

Locations

1 site across 1 country: United States